Table 4 |
||
|
Percentage of subjects for each treatment group reporting adverse events |
||
|
Adverse event |
Quetiapine (%, n) |
Placebo (%, n) |
|
|
||
|
Sedation |
75% (15) |
33.3%(7) |
|
Dry mouth |
15% (3) |
0 |
|
Headache |
15% (3) |
38% (8) |
|
Fatigue |
15% (3) |
19% (4) |
|
Irritability |
10% (2) |
4.7% (1) |
|
Impaired concentration |
10% (2) |
0 |
|
Dizziness |
5% (1) |
14.3% (3) |
|
Nausea |
5% (1) |
9.5% (2) |
|
Increased appetite |
5% (1) |
9.5% (2) |
|
Delayed ejaculation |
5% (1) |
0 |
|
Weight gain |
5% (1) |
0 |
|
Worsening mood |
5%(1) |
4.7%(1) |
|
Memory difficulties |
5%(1) |
0 |
|
Muscle aches |
5%(1) |
0 |
|
Abdominal tenderness |
5%(1) |
0 |
|
Slurred speech |
5%(1) |
0 |
|
|
||
|
Carey et al. BMC Psychiatry 2005 5:5 doi:10.1186/1471-244X-5-5 |
||
